Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 6-K

Psyence Biomedical Ltd.

PBMNASDAQEQUITYCurrent

SEC Filing

Filed Sep 23, 2026Accepted Sep 23, 2026, 7:00 AM EDTCIK 1985062Accession 0001213900-26-102358
Share

Company context

Psyence Biomedical Ltd. (Nasdaq: PBM) is a Nasdaq-listed company with its subsidiary, Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. It is the first life sciences biotechnology company focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine to be listed on Nasdaq. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.

Current securities

Recent company filings

  1. 6-K filingSep 14, 2026
  2. EFFECT filingSep 1, 2026
  3. S-8 filingAug 26, 2026
  4. F-3 filingAug 26, 2026
  5. 6-K filingAug 6, 2026

As-filed source

Primary evidence